How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,009 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Efficacy of sifalimumab for treatment of skin injury (SI) caused by systemic lupus erythematosus (SLE): a systematic review protocol of randomized controlled trials

Efficacy of sifalimumab for treatment of skin injury (SI) caused by systemic lupus erythematosus (SLE): a systematic review protocol of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

82. Chinese herbal formulas on steroid withdrawal in systemic lupus erythematosus: a systematic review based on TCM therapeutic principle

Chinese herbal formulas on steroid withdrawal in systemic lupus erythematosus: a systematic review based on TCM therapeutic principle Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

83. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). (PubMed)

Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). To identify patterns (clusters) of damage manifestation within a large cohort of juvenile SLE (jSLE) patients and evaluate their possible association with mortality.This is a multicentre, descriptive, cross-sectional study of a cohort of 345 jSLE patients from the Spanish Society of Rheumatology Lupus (...) Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics Damage Index. Using cluster analysis, groups of patients with similar patterns of damage manifestation were identified and compared.Mean age (years) ± S.D. at diagnosis was 14.2 ± 2.89; 88.7% were female and 93.4% were Caucasian. Mean SLICC/ACR DI ± S.D. was 1.27 ± 1.63. A total of 12 (3.5%) patients died. Three damage clusters were identified: Cluster 1 (72.7% of patients) presented a lower number

2018 Seminars in arthritis and rheumatism

84. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumab. (PubMed)

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. In a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State (LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb randomised controlled trial (RCT) (MUSE [NCT01438489]) and then utilize LLDAS to discriminate between anifrolumab and placebo.Patients received (...) (SRI[4]) and British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) (74/85[87%] and 62/84[74%] were also SRI[4] and BICLA responders, respectively; both nominal p<0.001). Only 74/159 (47%) of SRI(4) and 62/121 (51%) of BICLA responders reached LLDAS.Anifrolumab-treated patients achieved earlier LLDAS, and more spent at least half their observed time in LLDAS (OR vs. placebo; 300 mg: 3.04, 95% CI 1.34 to 6.92, nominal p=0.008; 1,000 mg: 2.17, 95% CI 0.93 to 5.03, nominal p

Full Text available with Trip Pro

2018 Annals of the Rheumatic Diseases

85. Predicting eventual development of lupus nephritis at the time of diagnosis of systemic lupus erythematosus. (PubMed)

Predicting eventual development of lupus nephritis at the time of diagnosis of systemic lupus erythematosus. To investigate factors predictive of future lupus nephritis development when systemic lupus erythematosus (SLE) is diagnosed.Patients with newly diagnosed SLE without renal manifestations were followed for development of lupus nephritis, comparing findings at baseline between those who did or did not develop nephritis. Albumin-to-globulin ratio (AGR) was calculated as albumin/(total (...) protein-albumin). Cox proportional hazard model was used to identify predictors of lupus nephritis.Of 278 patients, 241 did not and 37 did develop lupus nephritis during follow-up. On univariate analysis, young age, low C3, low C4, high anti-dsDNA titre, anti-Sm antibody, anti-RNP antibody and low AGR were associated with a higher risk of lupus nephritis. On multivariate analysis, factors predictive of nephritis were age [adjusted hazard ratio (aHR) 0.928, 95% confidence interval (CI): 0.895-0.961, p

2018 Seminars in arthritis and rheumatism

86. Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity (PubMed)

Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity Systemic lupus erythematosus (SLE) patients are at high risk of herpes zoster. Previously, we found increased immunoglobulin (Ig)G levels against varicella-zoster virus (VZV) in SLE patients compared to controls, while antibody levels against diphtheria and cellular immunity to VZV were decreased. We aimed to test our (...) or presence of VZV-IgM or VZV-DNA. Generalized estimating equations (GEE) were used to longitudinally analyse associations between antibody levels, lupus disease activity and medication use. Systemic Lupus Erythematosus Disease Activity Index, anti-double-stranded DNA and complement levels were used as indicators of lupus disease activity. Results A VZV reactivation was determined in 11 patients (33%). In at least five of them, herpes zoster was clinically overt. No association between SLE disease

Full Text available with Trip Pro

2018 Lupus

87. Gut Microbiota in Human Systemic Lupus Erythematosus and a Mouse Model of Lupus (PubMed)

Gut Microbiota in Human Systemic Lupus Erythematosus and a Mouse Model of Lupus Gut microbiota dysbiosis has been observed in a number of autoimmune diseases. However, the role of the gut microbiota in systemic lupus erythematosus (SLE), a prototypical autoimmune disease characterized by persistent inflammation in multiple organs of the body, remains elusive. Here we report the dynamics of the gut microbiota in a murine lupus model, NZB/W F1, as well as intestinal dysbiosis in a small group (...) of SLE patients with active disease. The composition of the gut microbiota changed markedly before and after the onset of lupus disease in NZB/W F1 mice, with greater diversity and increased representation of several bacterial species as lupus progressed from the predisease stage to the diseased stage. However, we did not control for age and the cage effect. Using dexamethasone as an intervention to treat SLE-like signs, we also found that a greater abundance of a group of lactobacilli (for which

Full Text available with Trip Pro

2018 Applied and environmental microbiology

88. Brief Report: A Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled, Multiple‐Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis (PubMed)

Brief Report: A Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled, Multiple‐Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis To evaluate the safety and potential efficacy of AMG 557, a fully human antibody directed against the inducible T cell costimulator ligand (ICOSL) in patients with systemic lupus erythematosus (SLE) with arthritis.In this phase Ib, randomized, double-blind, placebo-controlled study, patients (...) ) index, and medication discontinuation. The secondary/exploratory end points were changes in the tender and swollen joint counts, BILAG index scores (musculoskeletal, global), and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).The incidence of adverse events, most of which were mild, was similar between groups. LARI responses occurred in 3 of 10 patients receiving AMG 557 and 1 of 10 patients receiving placebo (P = 0.58). More patients in the AMG 557 group achieved a ≥4-point

Full Text available with Trip Pro

2018 Arthritis & rheumatology (Hoboken, N.J.)

89. The Involvement of MicroRNAs in Modulation of Innate and Adaptive Immunity in Systemic Lupus Erythematosus and Lupus Nephritis (PubMed)

The Involvement of MicroRNAs in Modulation of Innate and Adaptive Immunity in Systemic Lupus Erythematosus and Lupus Nephritis Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), represent a family of RNA molecules that do not translate into protein. Nevertheless, they have the ability to regulate gene expression and play an essential role in immune cell differentiation and function. MicroRNAs were found to be differentially expressed in various tissues, and changes in their expression have (...) been associated with several pathological processes. Yet, their roles in systemic lupus erythematosus (SLE) and lupus nephritis (LN) remain to be elucidated. Both SLE and LN are characterized by a complex dysfunction of the innate and adaptive immunity. Recently, significant findings have been made in understanding SLE through the use of genetic variant identification and expression pattern analysis and mouse models, as well as epigenetic analyses. Abnormalities in immune cell responses, cytokine

Full Text available with Trip Pro

2018 Journal of immunology research

90. B Cell-Related Circulating MicroRNAs With the Potential Value of Biomarkers in the Differential Diagnosis, and Distinguishment Between the Disease Activity and Lupus Nephritis for Systemic Lupus Erythematosus (PubMed)

B Cell-Related Circulating MicroRNAs With the Potential Value of Biomarkers in the Differential Diagnosis, and Distinguishment Between the Disease Activity and Lupus Nephritis for Systemic Lupus Erythematosus Our understanding of circulating microRNAs (miRNAs) related to systemic lupus erythematosus (SLE) remains very limited. In this study, we screened SLE-specific miRNAs in plasma from 42 B cell-related miRNAs by using miRNA PCR Array. The selected miRNAs were first confirmed in plasma (...) lower in SLE patients with low estimate glomerular filtration rate (eGFR < 60 ml/min/1.73 m2) (P < 0.05). The diagnostic potential of miR-15b for SLE disease activity and lupus nephritis (LN) with low eGFR was validated on an independent validation set with 69 SLE patients and a cross-validation set with 80 SLE patients. In summary, the signature of circulating miRNAs will provide novel biomarkers for the diagnosis of SLE and evaluation of disease activity and LN.

Full Text available with Trip Pro

2018 Frontiers in immunology

91. FLARE Lupus Research Study Systemic Lupus Erythematosus

FLARE Lupus Research Study Systemic Lupus Erythematosus FLARE Lupus Research Study Systemic Lupus Erythematosus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. FLARE Lupus Research Study Systemic Lupus (...) Summary: The first phase of this pilot study will assess changes in quality of life at the end of a 16-week Mymee program in patients with moderate to severe SLE. The second phase will assess changes in healthcare utilization and cost over a one year period after program end. Condition or disease Intervention/treatment Phase System; Lupus Erythematosus Behavioral: Mymee Program Not Applicable Detailed Description: Intervention Group The Intervention Group will enter daily tasks into the Mymee app

2018 Clinical Trials

92. Safety and Tolerability of Omalizumab, A Randomized Clinical Trial of Humanized anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus (STOP LUPUS). (PubMed)

Safety and Tolerability of Omalizumab, A Randomized Clinical Trial of Humanized anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus (STOP LUPUS). Autoreactive IgE antibodies have been implicated in the pathogenesis systemic lupus erythematosus (SLE). We hypothesized that omalizumab, a monoclonal antibody (mAb) binding IgE, may improve SLE activity by reducing type I IFN production by hampering plasmacytoid dendritic cells and basophil activation. This study assessed the safety (...) , tolerability, and clinical efficacy of omalizumab in mild to moderate SLE.Fifteen subjects with SLE and a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) of > 4 and elevated autoreactive IgE antibodies were randomized to receive omalizumab or placebo (2:1) for 16 weeks, followed by 16-week open label treatment and 4-week washout period. SLEDAI 2K, British Isles Lupus Assessment Group index (BILAG 2004) and Physician Global Assessment (PGA) were recorded at each visit. Type I interferon

2018 Arthritis & rheumatology (Hoboken, N.J.)

93. Isolated acute lupus pneumonitis as the initial presentation of systemic lupus erythematosus in an 8-year-old girl (PubMed)

Isolated acute lupus pneumonitis as the initial presentation of systemic lupus erythematosus in an 8-year-old girl Systemic lupus erythematosus (SLE) is a systemic autoimmune disease which has broad pleuropulmonary manifestations. One of the rare and mortal complications is acute lupus pneumonitis, which is reported very rarely, especially in childhood. Herein, we report an 8-year-old girl with isolated acute lupus pneumonitis as the initial presentation that required a lung biopsy (...) for diagnosis. Although she had improvement with the administration of steroids, steroid treatment was reduced due to the drug's side effects resulting in the addition of azathioprine and mycophenolate mofetil to the treatment regimen. After the new regimen failed to result in clinical improvement, hydroxychloroquine treatment was started and a significant improvement was observed. Acute lupus pneumonitis is an uncommon manifestation of SLE and diagnosis may be difficult in patients without other organ

Full Text available with Trip Pro

2018 Auto-Immunity Highlights

94. Bullous systemic lupus erythematosus associated with increased activity of lupus nephritis: a case report and review of the literature (PubMed)

Bullous systemic lupus erythematosus associated with increased activity of lupus nephritis: a case report and review of the literature 30206461 2018 11 14 1642-395X 35 4 2018 Aug Postepy dermatologii i alergologii Postepy Dermatol Alergol Bullous systemic lupus erythematosus associated with increased activity of lupus nephritis: a case report and review of the literature. 431-433 10.5114/ada.2018.77676 Żychowska Magdalena M Department of Dermatology, Venereology and Allergology, Wroclaw Medical (...) (13):1445 21720069 Ann Intern Med. 1982 Aug;97(2):165-70 7049027 Int J Dermatol. 1997 May;36(5):369-71 9199988 Oman Med J. 2016 Nov;31(6):453-455 27974963 Br J Dermatol. 1995 Jun;132(6):921-8 7662571 J Am Acad Dermatol. 1983 Dec;9(6):924-33 6358284 Lupus. 2014 Nov;23(13):1422-5 25074872

Full Text available with Trip Pro

2018 Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

95. Late-Onset Systemic Lupus Erythematosus With Lupus Nephritis in a 74-Year-Old Male: A Brief Case and Review (PubMed)

Late-Onset Systemic Lupus Erythematosus With Lupus Nephritis in a 74-Year-Old Male: A Brief Case and Review Late-onset systemic lupus erythematosus (SLE) represents a specific subgroup of SLE, and although there is no strict age cut-off, 50 years is commonly used as the minimum age for disease onset. In this report, we present a case of a 74-year-old male with late-onset SLE and biopsy-proven lupus nephritis (LN).A 74-year-old male was referred to the nephrology clinic with a rapidly rising (...) and cyclophosphamide. He was then placed on the Euro-Lupus Protocol.One year after the diagnosis, he was off dialysis, had no signs of fluid retention or uremia, and his creatinine had stabilized at ~ 330 µmol/L.To the best of our knowledge, this case represents the oldest known biopsy-confirmed case of late-onset SLE and LN. Late-onset SLE is uncommon and often overlooked as classical symptoms such as malar rash or photosensitivity may not be present. The American College of Rheumatology (ACR) guidelines

Full Text available with Trip Pro

2018 Canadian journal of kidney health and disease

96. Systemic lupus erythematosus of the urinary tract: focus on lupus cystitis (PubMed)

Systemic lupus erythematosus of the urinary tract: focus on lupus cystitis Systemic lupus erythematosus (SLE) frequently manifests as urinary tract disease, most commonly in the form of lupus nephritis. Bladder involvement in the disease course takes a subclinical form and may affect both children and adults. Lupus cystitis can precede SLE diagnosis and may present with very unspecific urinary and digestive tract symptoms or no symptoms at all. The exact mechanism of bladder inflammation (...) in lupus is not fully understood; however, histopathological studies suggest a possible role of immune complex-mediated small vessel vasculitis. Lupus cystitis is a rare SLE manifestation, but poses a challenge for physicians, due to its complex diagnostics and treatment.

Full Text available with Trip Pro

2018 Reumatologia

97. Polymorphism of keratin 1 associates with systemic lupus erythematosus and systemic sclerosis in a south Chinese population. (PubMed)

Polymorphism of keratin 1 associates with systemic lupus erythematosus and systemic sclerosis in a south Chinese population. Both systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) diseases are related to the genetic and environmental factors, causing damage to the skin. The mutations of keratin 1 gene (KRT1) were reported to associate with skin diseases. The single-nucleotide polymorphism (SNP, rs14024) and the indel polymorphism (cds-indel, rs267607656), consisting mostly

Full Text available with Trip Pro

2017 PLoS ONE

98. Corrigendum to "A Systematic Review of Peripheral and Central Nervous System Involvement of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome, and Associated Immunological Profiles". (PubMed)

Corrigendum to "A Systematic Review of Peripheral and Central Nervous System Involvement of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome, and Associated Immunological Profiles". [This corrects the article DOI: 10.1155/2015/910352.].

Full Text available with Trip Pro

2016 International journal of chronic diseases

99. What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus?

What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus? What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What treatments relieve arthritis and fatigue associated with systemic lupus (...) erythematosus? View/ Open Date 2014-10 Format Metadata Abstract Q: What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus? A: Hydroxychloroquine and chloroquine improve the arthritis associated with mild systemic lupus erythematosus (SLE)—producing a 50% reduction in arthritis flares and articular involvement—and have few adverse effects (strength of recommendation [SOR]: a, systematic review of randomized controlled trials [RCTs]). Methotrexate reduces arthralgias

2014 Clinical Inquiries

100. Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus. (PubMed)

Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that can involve nervous system commitment known as neuropsychiatric systemic lupus erythematosus (NPSLE). The diagnostic of NPSLE is complex because the symptoms range from focal symptoms (e.g., strokes, thrombotic events) to diffuse disorders affecting

2019 Autoimmunity reviews

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>